logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 14 of 14 Items
Showing 1 - 14 of 14 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (14)
  • CSV
  • BibTeX
  • EndNote
  • All Results (14)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

The development of a global research agenda and individual participant data platform for visceral leishmaniasis: challenges and future opportunities

Singh-Phulgenda S, Dahal P, Maguire BJ, Alvar J, Alves F,  et al.
2025-12-02 • Parasites and Vectors
2025-12-02 • Parasites and Vectors

BACKGROUND

Visceral leishmaniasis (VL) is one of the neglected tropical diseases (NTDs) listed by the World Health Organization (WHO). The disease is currently ...

Journal Article
|
Research
Journal Article
|
Protocol
Journal Article
|
Protocol
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Slide Presentation
Conference Material
|
Abstract
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Research & Publication Resources
|
Research Protocol
Journal Article
|
Research
Journal Article
|
Research

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R,  et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND
In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...

Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis

Munir A, Dahal P, Kumar R, Singh-Phulgenda S, Siddiqui NA,  et al.
2023-12-14 • BMJ Open
2023-12-14 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...

Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

Kumar R, Dahal P, Singh-Phulgenda S, Siddiqui NA, Munir A,  et al.
2023-10-28 • BMJ Open
2023-10-28 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...

Combination Treatment for Visceral Leishmaniasis Patients Co-infected with Human Immunodeficiency Virus in India

Mahajan R, Das P, Isaakidis P, Sunyoto T, Sagili KD,  et al.
2015-06-30 • Clinical Infectious Diseases
2015-06-30 • Clinical Infectious Diseases
There are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas of Bihar, India. These patients are...

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)

Burza S, Mahajan R, Singh A, van Griensven J, Pandey K,  et al.
2014-08-07 • PLOS Neglected Tropical Diseases
2014-08-07 • PLOS Neglected Tropical Diseases
Visceral Leishmaniasis (VL; also known as kala-azar) is an ultimately fatal disease endemic in the Indian state of Bihar, while HIV/AIDS is an emerging disease in this region. A 2011 obs...

Prevalence of asymptomatic Leishmania infection in people living with HIV (PLHIV) and progression to symptomatic visceral leishmaniasis in Bihar, India

Mahajan R, Owen SI, Kazmi S, Das P, Pandey K,  et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research

Prevalence of asymptomatic Leishmania infection in HIV-positive people and progression to symptomatic visceral leishmaniasis in Bihar, India.

Mahajan R, Owen SI, Kazmi S, Das P, Pandey K,  et al.
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
People co-infected with visceral leishmaniasis and HIV (VL-HIV) typically present with advanced HIV disease and in poor clinical condition. The reasons for this are comp...

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India

Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS,  et al.
2018-10-22 • PLOS Neglected Tropical Diseases
2018-10-22 • PLOS Neglected Tropical Diseases
BACKGROUND
In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown e...

Prevalence and determinants of asymptomatic Leishmania infection in HIV-infected individuals living within visceral leishmaniasis endemic areas of Bihar, India

Mahajan R, Owen SI, Pandey K, Kazmi S, Kumar V,  et al.
2022-08-30 • PLOS Neglected Tropical Diseases
2022-08-30 • PLOS Neglected Tropical Diseases
People living with HIV (PLHIV) have an increased risk of developing visceral leishmaniasis (VL) and poor outcomes compared to HIV negative individuals. Here, we aim to establish the prev...

Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India

Goyal V, Burza S, Pandey K, Singh SN, Singh RS,  et al.
2019-09-26 • PLOS Neglected Tropical Diseases
2019-09-26 • PLOS Neglected Tropical Diseases
BACKGROUND:
An earlier open label, prospective, non-randomized, non-comparative, multi-centric study conducted within public health facilities in Bihar, India (CTRI/2012/08/002891) ...

Evaluation of qPCR on blood and skin microbiopsies, peripheral blood buffy coat smear, and urine antigen ELISA for diagnosis and test of cure for visceral leishmaniasis in HIV-coinfected patients in India: a prospective cohort study

Owen SI, Burza S, Verma N, Mahajan R, Harshana A,  et al.
2021-04-30 • BMJ Open
2021-04-30 • BMJ Open
INTRODUCTION
HIV coinfection presents a challenge for diagnosis of visceral leishmaniasis (VL). Invasive splenic or bone marrow aspiration with microscopic visualisation of Leishmani...

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N,  et al.
2011-10-01 • Clinical Infectious Diseases
2011-10-01 • Clinical Infectious Diseases
Reports on treatment outcomes of visceral leishmaniasis (VL)-human immunodeficiency virus (HIV) coinfection in India are lacking. To our knowledge, none have studied the efficacy of lipo...

Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India

Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA,  et al.
2010-08-01 • American Journal of Tropical Medicine and Hygiene
2010-08-01 • American Journal of Tropical Medicine and Hygiene
We evaluated, through the prospective monitoring of 251 patients at Sadar Hospital in Bihar, India, the effectiveness and safety of 20 mg/kg body weight of liposomal amphotericin B for t...